Diamedica Therapeutics Stock Today
| DMAC Stock | USD 2.39 0.04 1.65% |
Performance0 of 100
| Odds Of DistressLess than 46
|
DiaMedica Therapeutics is trading at 2.39 as of the 15th of April 2024, a -1.65 percent decrease since the beginning of the trading day. The stock's open price was 2.43. DiaMedica Therapeutics has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for DiaMedica Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of October 2023 and ending today, the 15th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of January 2008 | Category Healthcare | Classification Health Care |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 37.96 M outstanding shares of which 202.17 K shares are currently shorted by private and institutional investors with about 4.75 trading days to cover. More on DiaMedica Therapeutics
Moving against DiaMedica Stock
| 0.49 | MRNA | Moderna Financial Report 2nd of May 2024 | PairCorr |
| 0.41 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 20th of May 2024
DiaMedica Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. DiaMedica Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding DiaMedica Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Dietrich MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering DiaMedica Therapeutics report their recommendations after researching DiaMedica Therapeutics' financial statements, talking to executives and customers, or listening in on DiaMedica Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering DiaMedica Therapeutics. The DiaMedica consensus assessment is calculated by taking the average forecast from all of the analysts covering DiaMedica Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to DiaMedica Therapeutics' liquidity, profitability, solvency, and operating efficiency, DiaMedica Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of DiaMedica Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
DiaMedica Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to DiaMedica Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand DiaMedica Therapeutics' financial leverage. It provides some insight into what part of DiaMedica Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
DiaMedica Therapeutics (DMAC) is traded on NASDAQ Exchange in USA. It is located in 301 Carlson Parkway, Minneapolis, MN, United States, 55305 and employs 18 people. DiaMedica Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 92.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DiaMedica Therapeutics's market, we take the total number of its shares issued and multiply it by DiaMedica Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. DiaMedica Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.96 M outstanding shares of which 202.17 K shares are currently shorted by private and institutional investors with about 4.75 trading days to cover.
DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45.
Check DiaMedica Therapeutics Probability Of Bankruptcy
Ownership AllocationDiaMedica Therapeutics holds a total of 37.96 Million outstanding shares. DiaMedica Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check DiaMedica Ownership Details
DiaMedica Stock Price Odds Analysis
What are DiaMedica Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of DiaMedica Therapeutics jumping above the current price in 90 days from now is close to 99%. The DiaMedica Therapeutics probability density function shows the probability of DiaMedica Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3345 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, DiaMedica Therapeutics will likely underperform. Additionally, diaMedica Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of DiaMedica Therapeutics to move above the current price in 90 days from now is close to 99 (This DiaMedica Therapeutics probability density function shows the probability of DiaMedica Stock to fall within a particular range of prices over 90 days) .
DiaMedica Stock Institutional Holders
Institutional Holdings refers to the ownership stake in DiaMedica Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of DiaMedica Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DiaMedica Therapeutics' value.| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2023-12-31 | 104.7 K | |
| State Street Corporation | 2023-12-31 | 66.6 K | |
| Catalyst Financial Partners Llc | 2023-12-31 | 36.3 K | |
| Bank Of New York Mellon Corp | 2023-12-31 | 34.2 K | |
| Millennium Management Llc | 2023-12-31 | 28.8 K | |
| Susquehanna International Group, Llp | 2023-12-31 | 27.6 K | |
| Jane Street Group, Llc | 2023-12-31 | 23.8 K | |
| Stonebridge Capital Advisors Llc | 20 K | ||
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 17 K | |
| Cooperman Leon G | 2023-12-31 | 883.6 K | |
| Vanguard Group Inc | 2023-12-31 | 802.2 K |
DiaMedica Therapeutics Historical Income Statement
DiaMedica Therapeutics Income Statement is one of the three primary financial statements used for reporting DiaMedica's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of DiaMedica Therapeutics revenue and expense. DiaMedica Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, DiaMedica Therapeutics' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 13.8 M, whereas Depreciation And Amortization is forecasted to decline to about 28.5 K. View More FundamentalsDiaMedica Stock Against Markets
Picking the right benchmark for DiaMedica Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in DiaMedica Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for DiaMedica Therapeutics is critical whether you are bullish or bearish towards DiaMedica Therapeutics at a given time. Please also check how DiaMedica Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in DiaMedica Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
DiaMedica Therapeutics Corporate Directors
DiaMedica Therapeutics corporate directors refer to members of a DiaMedica Therapeutics board of directors. The board of directors generally takes responsibility for the DiaMedica Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of DiaMedica Therapeutics' board members must vote for the resolution. The DiaMedica Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| James Parsons | Director | Profile | |
| Jerry Xiao | Director | Profile | |
| Michael Giuffre | Independent Director | Profile | |
| Harry Alcorn | Director | Profile |
How to buy DiaMedica Stock?
Before investing in DiaMedica Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in DiaMedica Therapeutics. To buy DiaMedica Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of DiaMedica Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase DiaMedica Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located DiaMedica Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased DiaMedica Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as DiaMedica Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy DiaMedica Stock please use our How to Invest in DiaMedica Therapeutics guide.
Already Invested in DiaMedica Therapeutics?
The danger of trading DiaMedica Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of DiaMedica Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than DiaMedica Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile DiaMedica Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.